1.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2805, E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181109, NCT00375674
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-3311, NCT00631371
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 108844, NCT00720941
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: AECM-0501007709, NYWCCC-0501007709, NCI-6981, 6981, NCT00121251
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4K-05-1, NCT00184015
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J0570, J0570, JHOC-00001107, NCI-6884, 6884, NCT00324870
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and over
Sponsor: NCI
Protocol IDs: NYWCCC-0511008257, 6896, NCI-6896, NCT00324740
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: UCSF06523, NCT00384969
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 44, CRAD001C2480, NCT00392821
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2107, NCT00715182
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 11570, NCT00934440
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-RCC-001, NCT00975806
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1131001, CVX-060-102, NCT00982657
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-02-C-0130, CC-02-C-0130, NCI-3654, 3654, NCT00033670
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: NCI
Protocol IDs: UMN-2001LS058, UMN-MT2001-10, NCT00303719
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AREN0321, AREN0321, NCT00335556
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 5633, NJ 3805, CINJ 080507, NCT00323791
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E4805, E4805, NCT00357760
|
|
20.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 43, AVF 3913s, NCT00455975
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0437, NCT00465179
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UNMC-08106, 081-06, NCT00496756
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0020, 08-C-0020, NCI-P07148, NCT00566995
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ 197-204, NCT00557609
|
